Roche ad­justs Avastin fran­chise de­fense plans as PhII suc­ces­sor fails a key study

Vanu­cizum­ab was sup­posed to be Roche’s an­swer to the biosim­i­lars of Avastin that are now steadi­ly wind­ing their way through the clin­ic on a short …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.